On December 12 at 10:00 CET, InDex CEO Peter Zerhouni will give an overview of how the company sees the way forward towards phase III based on the successful phase IIb study CONDUCT with the drug candidate cobitolimod. The presentation concludes with a Q&A session together with InDex Pharmaceuticals Chairman of the Board Wenche Rolfsen and Board Member Lennart Hansson.
The presentation will be held in Swedish and can be followed at https://www.redeye.se/events#/event/584954. There will be an opportunity to participate on site in Redeye’s premises at Mäster Samuelsgatan 15, floor 10, in Stockholm. The registration is made via https://www.lyyti.fi/reg/Index_Pharmaceuticals__12_dec_3010